Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04926467
Recruitment Status : Not yet recruiting
First Posted : June 15, 2021
Last Update Posted : June 15, 2021
Sponsor:
Information provided by (Responsible Party):
Baylor Research Institute

Brief Summary:
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Drug: Anakinra Phase 2

Detailed Description:

This is an open-label, single-arm, prospective phase II study conducted by Baylor Scott and White Research Institute in Dallas.

The study will enroll patients with pancreatic adenocarcinoma that are planned to receive pre-operative chemotherapy followed by surgical resection and post operative treatment. Local surgical/biopsy and pathology reports will constitute adequate documentation of histology/cytology for study inclusion.

Patients will receive pre- and post-operative chemotherapy plus Anakinra. Specifically, the pre-operative chemotherapy regimen will be a combination of Nab-paclitaxel, gemcitabine and cisplatin, while post-operative chemotherapy will use 5-Fluorouracil, oxaliplatin, and irinotecan. Patients will also receive growth factor (Neupogen followed by Neulasta) for safety and to ensure that treatment is not delayed due to neutropenic effects of chemotherapy.

Anakinra will be self-administered by the participants through out the treatment period. A treatment break of 2 days will be given prior to the surgery day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase II Study of Chemotherapy + Anakinra in Patients With Resectable, Locally Advanced or Potentially Resectable Pancreatic Adenocarcinoma (PDAC)
Estimated Study Start Date : June 2021
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2026

Resource links provided by the National Library of Medicine

Drug Information available for: Anakinra

Arm Intervention/treatment
Experimental: Anakinra plus Chemotherapy
Patients will receive Anakinra during both pre-operative chemotherapy with Nab-paclitaxel, gemcitabine and cisplatin, followed by surgery and post-operative chemotherapy with 5-fluorouracil, oxaliplatin, and irinotecan.
Drug: Anakinra

Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.

Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8.





Primary Outcome Measures :
  1. To determine the percentage of patients that have a normalization of CA19-9 after pre-op treatment with the combination of nab-paclitaxel (abraxane), gemcitabine, cisplatin and anakinra. [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. To determine the effect of anakinra in combination with perioperative chemotherapy on overall survival (OS) of PDAC patients. A benchmark of 24 months OS will be used to determine how many patients meet or exceed this goal. [ Time Frame: 24 months ]
  2. To determine the effect of anakinra in combination with perioperative chemotherapy on the median disease free survival (DFS). A benchmark of 12 months DFS will be used to determine how many patients meet or exceed this goal. [ Time Frame: 12 months ]
  3. To determine the effect of anakinra in combination with perioperative chemotherapy on response rate [ Time Frame: 24 months ]
  4. To determine the R0 resection rates (complete tumor removal with negative resection margins) obtained with anakinra + pre-operative chemotherapy. [ Time Frame: 24 months ]
  5. To describe the effect of anakinra in combination with perioperative chemotherapy on the prevalence and severity of pain by monitoring patients' pain level using memorial pain assessment card (MPAC). [ Time Frame: 24 months ]
  6. To determine the effect of anakinra in combination with perioperative chemotherapy on patients' health-related quality of life by monitoring patients using EORTC quality of life survey questionnaire (EORTC QLQ-C30). [ Time Frame: 24 months ]
  7. To determine the effect of anakinra in combination with perioperative chemotherapy on the inflammasomes ( IL6, CRP, IL1α and IL1β) in blood and in the resected pathology specimens. [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A patient will be eligible for inclusion in this study if he or she meets all of the following criteria:

    1. 18 years of age or older
    2. Histologically or Cytologically confirmed pancreatic ductal adenocarcinoma. Mixed subtypes of adenocarcinoma are acceptable as long as majority of cells are ductal adenocarcinoma.
    3. Resectable, locally advanced or potentially resectable pancreatic adenocarcinoma
    4. American Joint Committee on Cancer (AJCC) Stage I-III Pancreatic carcinoma.
    5. Patient has Eastern Cooperative Oncology Group( ECOG ) Performance Status 0 to 1
    6. Serum albumin ≥2.0 g/dL.
    7. Adequate hematologic function as defined by:

      1. Absolute neutrophil count (ANC) ≥1500/mm3;
      2. Platelets ≥70,000 x 10^3/µl;
      3. Hemoglobin ≥9 g/dL (in the absence of red blood transfusion).
    8. Adequate liver function, as defined by:

      1. Serum total bilirubin ≤2 x ULN mg/dL, prior to initiation of treatment.
      2. ALT (SGPT) and AST (SGOT) ≤2.5 x upper limit of normal (ULN).
    9. Adequate renal function, as defined by serum creatinine≤ 1.5 x ULN, or creatinine clearance ≥50 mL/min
    10. Women of child bearing potential and men must agree to use contraception throughout the study and for one month after the last anakinra administration.
    11. Subjects must understand and sign the informed consent form
    12. Patients must be accessible for treatment and follow-up.

Exclusion Criteria:

  • A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

    1. <18 years of age
    2. History of organ transplant.
    3. Patients with islet cell neoplasms
    4. Patients with stage IV pancreatic carcinoma
    5. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
    6. Known active infection with hepatitis B or hepatitis C
    7. Presence of clinically significant cirrhosis as determined by the investigator
    8. Known HIV positive status.
    9. Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
    10. Major surgery or vascular device placement within 2 weeks prior to Day 1 of treatment in study
    11. Prior chemotherapy or radiation for pancreatic cancer
    12. History of allergy or hypersensitivity to the study drugs
    13. Patient is enrolled in any outside therapeutic clinical protocol or investigational trial with an investigational drug within 5 half-lives prior to Study ID assignment
    14. Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor
    15. Other malignancy within five years(except cutaneous, non-melanoma malignancies or cervical carcinoma in site), unless the probability of recurrence of the prior malignancy is <5% as determined by the Principal Investigator based on available information.
    16. Significant cardiac disease (uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias) within the last six months.
    17. Other severe and/or uncontrolled medical conditions (e.g: prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation) or other conditions deemed by investigator as unsuitable for participation/enrollment
    18. Peripheral sensory neuropathy > or equal to grade 2 at baseline
    19. Abnormal liver function tests as follows:

      1. Total bilirubin of > 2 x ULN
      2. AST or ALT > 5x ULN
    20. Serum albumin ˂ 2.0 g/dL.
    21. Abnormal hematologic function as follows :

      1. Absolute neutrophil count (ANC) ˂ 1500/mm3;
      2. Platelets ˂ 70,000 x 10^3/µl;
      3. Hemoglobin ˂ 9 g/dL (in the absence of red blood transfusion).
    22. Pregnant or nursing women
    23. No signed Informed consent form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04926467


Contacts
Layout table for location contacts
Contact: Heather Williams, MS (214) 818-7879 Heather.Williams1@BSWHealth.org
Contact: Joyce Ghormley (214) 818-8961 Joyce.Ghormley@BSWHealth.org

Locations
Layout table for location information
United States, Texas
Baylor University Medical Center, Charles A Sammons Cancer Center
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Baylor Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Carlos Becerra, MD Charles A. Sammons Cancer Center/Texas Oncology
Layout table for additonal information
Responsible Party: Baylor Research Institute
ClinicalTrials.gov Identifier: NCT04926467    
Other Study ID Numbers: 020-476
First Posted: June 15, 2021    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents